

17th Meeting of Balkan Clinical Laboratory Federation &

5th Macedonian National Congress of Medical Biochemists Ohrid, Republic of Macedonia, September 16–19, 2009 Abstracts volume

BALKAN JOURNAL OF CLINICAL LABORATORY

XVII, 09, 1

17th Meeting of Balkan Clinical Laboratory Federation &

5th Macedonian National Congress of Medical Biochemists Ohrid, Republic of Macedonia, September 16–19, 2009 Abstracts volume

Proceedings

of the 17th Meeting Of The Balkan Clinical Laboratory Federation

8

5th Macedonian National Congress of Medical Biochemists

Ohrid, Republic of Macedonia September 16–19, 2009

Organizers:

Macedonian Society of Medical Biochemists
University Clinic of Clinical Biochemistry, Skopje

Department of Medical and Experimental Biochemistry,

Medical Faculty, "Ss Cyril and Methodius" University, Skopje, Republic of Macedonia BJCL

Material and methods: The study included 80 children of average of 13.4±0.3 years. The children were divided into two groups according to caries risk (low and high caries risk groups). Two samples of saliva-unstimulated and stimulated one were taken from each child. Ph value and bicarbonate buffer levels were estimated in both groups of saliva samples.

Results: We found that the mean bicarbonate concentration in unstimulated saliva at a pH of 6.7 was 4.2 mmol/l, and in stimulated saliva at a pH of 7.2 it was 9.6 mmol/l. In children with low caries risk, both unstimulated and stimulated saliva show significantly higher bicarbonate buffer concentrations (p<0.001) as well as pH values.

We have shown that a high salivation rate for unstimulated and stimulated whole saliva implies the presence of high bicarbonate concentration, a more alkaline pH and a high buffer capacity. In contrast low rate of secretion imply a lower bicarbonate concentration, a more acidic pH and a lesser buffer capacity.

Conclusions: The results of this examination with children, i.e. the values of the bicarbonates in saliva, may serve as parameters for determining the caries risk patients, and according to that, we can plan and carry appropriate caries-preventive measures.

PP-106

LEVELS OF CALCITONIN GENE -RELATED PEPTIDE IN SALIVA OF PATIENTS WITH BURNING MOUTH SYNDROME

Obrenovic R¹, Zidverc-Trajkovic J², Stanimirovic S³, Tajti J⁴, Vécsei L⁴, Gardi J⁵, Németh J⁵, Milija-Mijajlovic M², Sternic N², Jankovic Lj.³

Institute of Medical Biochemistry, Clinical Center of Serbia,

²Institute of Neurology, Clinical Center of Serbia, ³Clinic for Periodontology and Oral medicine, Faculty of Stomatology, University of Belgrade, Belgrade, Serbia; ⁴Department of Neurology, Albert Szent-Gyorgyi Medical University, Szeged, Hungary; 41st Department of Internal Medicine, Albert Szent-Gyorgyi Medical University, Szeged, Hungary;

⁵Department of Pharmacology and Pharmacotherapy, University of Debrecen, Debrecen, Hungary E-mail: radao@eunet.yu

Backround: Burning mouth syndrome (BMS) is an intraoral burning sensation for which no medical or dental cause can be found. Recent studies suggest that primary neuropathic dysfunction might be involved in the pathogenesis of BMS. Calcitonin gene-related peptide (CGRP) plays an important role in the development of pain and serves as a biological marker of trigeminovascular activation. The aim of this study was to determine the levels of CGRP

in the saliva of BMS patients. All patients underwent a general medical examination, a detailed blood test examination. Oral infections were ruled out by microbiological culture.

Methods: The saliva was collected for 15 min as unstimulated salivary flow. stored in ice bath and centrifuged at 1600 g on -4°C for 10 min. The supernatants were frozen at -80°C. Measurements of CGRP levels were performed at the University of Szeged, Hungary by RIA method in 78 BMS patients and 16 healthy subjects. CGRP antiserum was provided by T. Gorcs, Semmelweis Medical University, Budapest.

Results: Comparison of CGRP values between the examined group of patients and the control group showed lower values in patients (2.93±1.43 nmol/l) than in controls (3.45±0.81 nmol/l) without significant difference. CGRP levels were significantly higher in BMS patients with longer disease duration. No significant difference was found in CGRP levels of BMS patients according to gender and age.

Conclusions: The levels of CGRP were non-significantly decreased in BMS patients in comparison to healthy subjects. These results suggest that trigeminal nerve degeneration may be the underlying cause of BMS.

PP-107

PGE, CONCENTRATION IN TEETH PULP TISSUE AS A MARKER FOR THE EFFECTIVENES OF DIFFERENT TYPES OF TREATMENT FOR PERIODONTOPATHY

Gjorgoski I¹, Peshevska S⁴, Mladenov M¹, Hadzhi-Petrushev N¹, Atanasovska B¹, Spasov M², Davcheva O.³

¹Faculty of Natural Sciences and Mathematics – Skopje,

²Faculty of Medical Sciences - Stip,

³Faculty of Medicine - Skopje,

⁴Faculty Dental Medicine - Skopje, R. Macedonia E-mail: icko@iunona.pmf.ukim.edu.mk

Introduction: Activation of the immune system, followed by an increase in the concentration of different immune mediators (among which is found PGE₂) is observed during different types of infections and diseases. In our experiment, we monitored the concentration of PGE₂ in patients with generalized periodontopathy. The disease is characterized by severe inflammation of the gingival tissue.

The aim of our work: was to determine the effectiveness of different types of therapy for periodon-topathy.

Material and methods: We obtained tissue samples from the following groups of patients: control (healthy), untreated periodontopathic, periodonto-

salat tertera salt material patie



pathic treated with conservative therapy, and periodontopathic treated with laser therapy represented by 5 laser treatments or 10 laser treatments.

PGE₂ levels were determined using a non-radioactive enzyme-based immunoassay (PGE₂ EIA, Sigma-Aldrich, Inc.).

Results: Our results have shown that compared to healthy tissue, untreated periodontopathic samples contain significantly higher concentration of PGE₂ (p<0.05). The conservative therapy significantly decreases the level of PGE2 (compared to the untreated periodontopathic samples) (p<0.05). The 5 and 10 laser treatments are even more effective in reducing the inflammation and lowering the concentration of PGE₂. The greatest reduction of PGE₂ concentration is observed in the samples treated with 10 laser treatments, but the mean concentration of PGE₂ in these tissues is still significantly higher (p<0.05) than the concentration of PGE₂ in healthy tissue.

We conclude that: PGE₂ is a relevant indicator for the disease and treatment progress. Concerning the examined therapies, we would recommend further increase in the number of laser treatments.

168

P		R		Shishenkov M.	OP-14
Padureanu V.	PP-114	Radivojevic V.	PP-057, PP-058	Shishovska M.	PP-175
Palchevska S.	PP-049	Radisic Bosic		Shkodrani E.	PP-070, PP-161
Palevska S.	PP-001	Radakovic A.	PP-047	Shumarac Z.	PL-18
Palibrk I.	PP-31	Radović V.	PP-091	Shushleski D.	PP-123
Panaitesku E.	PP-153	Radulescu R.	OP-02	Shubeska-Strat	trova S. PP-057,
	PP-062, PP-140	Rajas F.	PP-122	PP-058	, PP-140, PP-191
Panovski M.	PP-029	Rasic D.	PP-125	Shumanska Zh	. PP-169
Panov S.	PP-122	Rasic J.	PP-125	Shtakleva M.	PP-128
Panjeta M.	PP-178	Rašović S.	Op-05, PP-180	Shyti E.	OP-13
Pap D.	PP-003	Refatllari E.	OP-10, PP-016,	Sladojevic N.	PP-043
Papesh J.	PP-117, PP-148		PP-138, PP-141	Sofić E.	LP-07
Papraniku E.	PP-025	Rendeska M.	PP-044	Sokoli T.	PP-185, PP-186
Paqarizi H.	PP-074	Rendevski S.	PP-184	Sokolović D.	OP-06
Pashoski A.	PP-018, PP-084	Reqi H.	PP-075		vska A. PP-105
Pavlova S.	PP-048	Rifati A.	PP-130	Sözmen B.	PP-026
Pavlova V.	PP-177	Ristic T.	PP-011, PP-013	Spasic G.	PP-047
Paviovic D.	OP-04, OP-06	Ristevska E.	PP-110	Spasov M.	PP-107, PP-131
Pavlovic R.	OP-04, OP-06	Ristovska G.	PP-061	Spasovski D.	PP-115
Pejcic T.	PP-158	Ristovska V.	PP-036	Spiroski M.	LP-03, PP-007,
Pencheva B.	PP-40		kovska N. PP-052		, PP-083, PP-111
Pepi D.	PP-138	Ristovski V.	PP-005		, PP-022, PP-109
Percan V. Perišić Z.	PP-068	Ristoski T.	PP-129	Springle A.	W-02
Peshevska S.	PP-012	Rizos C. V.	PP-009	Stafilov T.	PP-037, PP-193
Petlevski R.	PP-107	Rizos D.	PL-17	Stamatovic S.	PP-179
	PP-134 I. PP-019, PP-111	Rogoz S.	PP-114, PP-116	Stamenkova S.	PP-142
Petkovska V.	PP-117	Rushkovska T.	*	Stamkova M.	PP-183
Petrela E.	PP-137	Rustemi A.	PP-089	Stanimirovic S.	PP-106
	, PP-150, PP-151	S Sabata A	mm ann	Stankovic I. Stankovic S.	PP-158
Petreski D.	PP-172	Sabriu A.	PP-128	Stanković 5. Stanković-Ferle	PP-030
Petrovska E.	PP-059, PP-086,	Saglam N. Sahin D.	PP-135	Statikovic-Ferie	
	PP-088	Sandevska E.	PP-097	Stanojkovic M.	PP-012, PP-013 PP-078
Petrovska S.	PP-156	Sapunov S.	PP-111 PP-099	Staykova J.	PP-048
Petrovski Z.	PP-072, PP-087	Sari S.	PP-127	Stefanovic N.	PP-043
Petrou Ch.	PP-092	Sarkić M.	PP-085	Stekel H.	PL-04, PL-05
Piperski V.	PP-125	Scarlat P.	PP-116	Sterjovska-Alek	
Plashevska-Kai	anfilska D.LP-04	Sdranis Y.	OP-15		PP-131
Pontet F.	PL-09	Sekulovski P.	PP-187, PP-194	Sternic N.	PP-106
Popa Gh.	PP-144	Sela S.	PP-025	Stoiljkovic S.	PP-158
Pop-Kostova A.	PP-010	Selim Gj.	PP-081		PP-054, PP-174,
Poposka Z.	PP-175	Semanaj V.	OP-13	•	PP-176
Poposki G.	PP-025, PP-136	Semenakova-C		Stojanović I.	OP-06
Popova M.	PP-094		PP-169, PP-184	Stojanovic S.	PP-166, PP-168
Popovic D.	PP-179	Semerci T.	PP-090	Stojanov D.	PP-182
Popovic M.	PP-124, PP-125,	Semoska V.	PP-139	Stojanovska-Dir	
	PP-132, PP-133	Sen A.	OP-03		PP-187, PP-194
Prilepchanska L		Sepici-Dincel A	.PP-097, PP-102,	Stojčević-Maleti	
	PP-119		PP-103	Stojcevska E.	PP-131
Prtenjak G.	PP-147	Silosi C.	PP-114, PP-116	Stojkovska S.	PP-169
Purice M.	OP-08	Silosi I,	PP-114, PP-116	Stojkovski V.	PP-079, PP-187,
n	es.	Simjanoska S.	PP-064		PP-192, PP-194
Q Olivining C		Shabani M.	PP-038, PP-041,	Stolic A.	PP-101
Qirjako G.	OP-10, PP-141,		PP-062, PP-075	Strezova A.	PP-111
	PP-185, PP-186	Shannan G.	OL, PL-01,	Sulcebe G.	OP-13
		Shikole A.	PP-036, PP-045		